Nada Hamad
The University of Notre Dame Australia, UNSW Sydney, Royal Australasian College of Medical Administrators, The University of Sydney, Australia and New Zealand Transplant and Cellular Therapies Limited
Research areas: Medicine · Hematology · Hematopoietic Stem Cell Transplantation · Lymphoma Diagnosis and Treatment · Chronic Lymphocytic Leukemia Research
0000-0001-7929-1450
About
Prof Nada Hamad BSc, MSc Forensic (Hons), MBBS (Hons), FRACP, FRCPA, FRCP, FRCPE, AFRACMA, GAICD, GAICG, SpecCert Clinical Research (Oncology)
Professor Nada Hamad is a clinical and laboratory haematologist and transplant and cellular therapies physician in Sydney, Australia, and an internationally recognised leader in blood cancer, cellular therapy and health equity.
She is President of Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) and Chair of the ANZTCT Registry. She is a Conjoint Professor of Medicine at the University of New South Wales and an Adjunct Professor at the University of Notre Dame Australia, a Fulbright Senior Scholar, and the Australian representative on the World Health Organization Bone Marrow Transplantation Taskforce. She is immediate past Chair of the NSW Agency for Clinical Innovation Bone Marrow Transplant Network and of the ALLG Transplant and Cellular Therapies group.
Her clinical and research expertise spans haematological malignancy, allogeneic transplantation and cellular therapies including CAR T cell therapy, and clinical trials and drug development, with a Specialist Certificate in Clinical Research (Oncology). She is an internationally recognised expert and advocate in intersectional medicine, equity, diversity and inclusion and culturally safe care, with a focus on equitable access to transplantation and cellular therapies. She has 141 publications and an active program of research, teaching and mentoring.
She completed bone marrow transplant and lymphoma fellowships at the Princess Margaret Cancer Centre, University of Toronto, and holds qualifications as a Graduate of the Australian Institute of Company Directors and the Australian Institute of Clinical Governance, with certification in artificial intelligence in health care from Harvard.
Employment
-
The University of Notre Dame Australia Adjunct Professor2024 - Present
-
University of New South Wales Conjoint Professor2024 - Present
- 2019 - Present
-
St Vincent's Hospital Haematologist2016 - Present
Education
- 2023 - Present
-
University of Sydney MBBS Hons2005 - Present
-
University of Auckland MSc Forensic Hons2000 - Present
Projects & Funding
Projects & funding information is unavailable.
Publications (288)
- A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants – a study fr… Save
- Erratum to: "The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients". Save
- ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand. Save
- Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis. Save
- Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses. Save
- LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma. Save
- Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study. Save
- Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study. Save
- Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial. Save
- Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care Save
- A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT) Save
- Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study. Save
- Haematological cancer in pregnancy in New South Wales, Australia: A population-based retrospective cohort study. Save
- ASSOCIATION BETWEEN BUSULFAN EXPOSURE AND OVERALL SURVIVAL AND TOXICITY IN HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANT WITH MYELOABLATIVE CONDITIONING - A PROSPECTIVE, MULTICENTRE ANALYSIS Save
- Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study Save
- Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation. Save
- Intersectionality in healthcare leadership: a scoping review on the career experiences of racially and ethnically minoritised women health professionals. Save
- Long-term outcome following vertebroplasty or bone cementoplasty in multiple myeloma patients. Save
- Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843. Save
- The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. Save